zimmytws/iStock by way of Getty Photographs
Zura’s just lately public biography (NASDAQ: ZURA) shares fell 11% of their debut session after the British immunology drugmaker’s merger with SPAC JATT Acquisition Corp. (JATT).
Zura shares opened at $7.94 and later closed at $7.24. JATT shares closed at $8.16 on Friday, down 24% from $10.75 on Thursday, in keeping with Dow Jones.
The SPAC introduced shareholder approval of the deal after the market closed on Thursday, and the closing was introduced on Monday.
The merger settlement, first introduced in June, valued the mixed firm at $215 million.
London-based Zura has two drug candidates in scientific trials for situations comparable to alopecia, diabetes, COPD and bronchial asthma.
JATT held an preliminary public providing in July 2021, elevating $139 million.
